Legacy Capital Wealth Partners LLC Takes $456,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Legacy Capital Wealth Partners LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, HoldingsChannel reports. The firm bought 4,318 shares of the medical equipment provider’s stock, valued at approximately $456,000.

Several other institutional investors have also modified their holdings of ZBH. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the third quarter valued at about $28,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet in the third quarter valued at about $35,000. Finally, Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $100.52 on Monday. The company’s 50 day simple moving average is $106.34 and its 200-day simple moving average is $107.69. The company has a market capitalization of $20.01 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company earned $2.20 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ZBH shares. Truist Financial reissued a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Barclays decreased their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.